Product image of Lenalidomide Cf (Lenalidomide) supplied by GNH India

Lenalidomide Cf

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Cf (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Cf, is an immunomodulatory drug presented as an oral tablet (strength not specified) for oral use. It is used in the treatment of multiple myeloma and myelodysplastic syndromes in adult patients.

GNH India supplies Lenalidomide Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from comprehensive regulatory support and timely delivery across multiple regions.

Manufacturer / TM Owner

Centrafarm B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is employed in hematologic malignancies and related bone‑marrow disorders, targeting disease pathways that drive abnormal cell growth.

  • Multiple myeloma: improves progression‑free and overall survival in eligible patients.
  • Myelodysplastic syndromes with del(5q): reduces transfusion dependence and may improve blood counts.
  • Relapsed or refractory disease: offers a therapeutic option after prior therapies have failed.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering substrate specificity and promoting ubiquitination and proteasomal degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). This leads to anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that inhibit malignant plasma cell growth and restore immune surveillance.

Side Effects

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Fatigue: persistent tiredness affecting daily activities.
  • Diarrhea: loose stools that may require hydration.
  • Rash: skin irritation or erythema.
  • Nausea: upset stomach, sometimes with vomiting.
  • Cytopenias: reduced white blood cells, red blood cells, or platelets.
  • Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Severe infections: opportunistic or bacterial infections requiring prompt treatment.
  • Secondary malignancies: emergence of new cancers during therapy.
  • Hepatotoxicity: significant liver enzyme elevations.
  • Cardiac arrhythmias: irregular heart rhythms in susceptible patients.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor laboratory parameters regularly.

  • Pregnancy risk: avoid use in pregnant women; teratogenic potential requires effective contraception.
  • Renal function: adjust monitoring for patients with impaired kidney function.
  • Hepatic function: assess liver enzymes before and during treatment.
  • Thrombotic risk: consider prophylactic anticoagulation in high‑risk individuals.
  • Infection vigilance: monitor for signs of infection and treat promptly.
  • Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Avoid Interactions

Lenalidomide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce lenalidomide exposure.
  • Anticoagulants: increased risk of bleeding when combined with lenalidomide.

Moderate Interactions (Monitor Closely)

  • Immunosuppressants: heightened infection risk.
  • NSAIDs: may exacerbate renal toxicity.
  • Vaccines: live vaccines should be avoided during therapy.

Frequently Asked Questions

Lenalidomide Cf is indicated for the treatment of adult patients with multiple myeloma and for myelodysplastic syndromes that have a deletion of chromosome 5q. It may also be used in relapsed or refractory disease when other therapies have not been effective.

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, causing the targeted degradation of transcription factors Ikaros and Aiolos. This results in anti‑angiogenic, immunomodulatory, and anti‑proliferative actions that suppress malignant plasma cells and enhance immune surveillance.

The prescribed dose of Lenalidomide Cf is determined by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Dosing regimens are individualized and should follow the prescriber's instructions.

Lenalidomide is classified as teratogenic and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception before, during, and after treatment. Safety during breastfeeding has not been established, and nursing is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, can be combined with dexamethasone or other agents, and has demonstrated efficacy in prolonging progression‑free survival, especially in patients with specific cytogenetic profiles.

Store Lenalidomide Cf at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, heat, and direct sunlight to maintain stability and potency.

Lenalidomide Cf is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless otherwise instructed.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe infections, secondary malignancies, significant liver toxicity, and life‑threatening hematologic abnormalities like neutropenia or thrombocytopenia. Patients should be monitored closely for these events.

Lenalidomide Cf should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled infections or severe renal impairment without appropriate dose adjustment. Clinicians must evaluate each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT